Core Viewpoint - Novo Nordisk has officially launched the long-acting recombinant coagulation factor VIII, Nuwiq, in mainland China, marking it as the first and only approved treatment for Hemophilia A in the country, which enhances patient accessibility to medication and introduces a new treatment phase for Hemophilia A patients in China [1][3]. Group 1: Product Launch and Market Impact - Nuwiq is now included in the new national medical insurance directory, significantly reducing the treatment burden for patients and addressing the issue of affordability for innovative drugs [4]. - The launch of Nuwiq fills a gap in long-term treatment options for Hemophilia A, which affects approximately 80%-85% of all hemophilia patients [3]. Group 2: Clinical Efficacy and Safety - Clinical trials, such as the Pathfinder105 study, demonstrated that patients receiving preventive treatment with Nuwiq had a median annualized bleeding rate (ABR) of 0.00, with 69.4% of patients experiencing zero bleeding events and a hemostatic success rate of 94.8% [3]. - Nuwiq extends the half-life of coagulation factor VIII to 19 hours, which is 1.6 times longer than standard formulations, allowing for a reduction of 50%-71% in intravenous injection frequency, thus improving treatment adherence [3]. Group 3: Future Commitment and Goals - Novo Nordisk aims to continue enhancing drug accessibility for Hemophilia patients in China and is committed to improving patient service systems to support the "Healthy China 2030" initiative [4].